Physician profile
Roslyn B Mannon
NPI 1558583377
$64,311.85
in general payments reported to CMS, 2019-2025
9 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $522 · 2021: $5,036 · 2022: $1,600 · 2024: $26K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $2,973 · Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,687.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,422.03 |
| Travel and Lodging | $2,973.42 |
| Food and Beverage | $756.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25,401.76 | 2024-2025 | |
| Csl Behring | $19,669.48 | 2019-2025 | |
| Biogen, INC. | $8,555.71 | 2024-2025 | |
| Genzyme Corporation | $5,990.48 | 2019 | |
| Alexion Pharmaceuticals, INC. | $3,375.87 | 2024 | |
| Chiesi USA, INC. | $1,100.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $83.19 | 2022 | |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $60.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roslyn Mannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.